Related Experiment Video

Updated: Jun 12, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Pharmacological prevention and management of restenosis

Klaus A Tiroch1, Robert A Byrne, Adnan Kastrati

  • 1Deutsches Herzzentrum München, Lazarettstrasse 36, D-80636 Munich, Germany. klaustiroch@hotmail.com

Expert Opinion on Pharmacotherapy
|May 22, 2010
PubMed

Insights

Drug-eluting stents effectively manage obstructive arterial disease restenosis, but delayed healing necessitates further research into optimal treatment strategies for this challenging clinical entity.

Area of Science:

  • Cardiovascular Interventions
  • Vascular Biology
  • Interventional Cardiology

Background:

  • Percutaneous intervention is a key treatment for obstructive arterial disease.
  • Restenosis remains a significant limitation despite therapeutic advancements.
  • Effective management of restenosis is crucial for long-term patient outcomes.

Purpose of the Study:

  • To review the literature on preventing and managing restenosis after percutaneous intervention.
  • To evaluate systemic and local drug delivery methods for restenosis.
  • To discuss current and emerging treatment options for restenosis.

Main Methods:

  • Comprehensive literature review of restenosis prevention and management.
  • Analysis of systemic pharmacological approaches.
  • Evaluation of local drug delivery, including drug-eluting stents (DES).

Main Results:

  • Systemic therapies show limited long-term efficacy for restenosis.
  • Drug-eluting stents (DES) are highly effective but may cause delayed healing.
  • Optimal management strategies for DES restenosis are still under investigation.

Conclusions:

  • Current restenosis prevention and treatment methods are effective but not fully satisfactory.
  • Further research is needed to optimize therapies and improve patient outcomes.
  • Addressing delayed healing associated with DES is a key area for future development.
Abstract

More Related Videos

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...